Non-muscle-invasive bladder cancer: An overview of potential new treatment options
| Autor: | Joan Palou Redorta, Thomas E. Hutson, Alberto Briganti, Oscar Rodriguez Faba, Grégoire Robert, Rossano Cesari, Subramanian Hariharan, Neal D. Shore, Gary D. Steinberg |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Urology medicine.medical_treatment 030232 urology & nephrology Disease Targeted therapy 03 medical and health sciences 0302 clinical medicine medicine Humans Intensive care medicine Immune Checkpoint Inhibitors Chemotherapy Bladder cancer medicine.diagnostic_test business.industry Cystoscopy medicine.disease Review article Clinical trial Administration Intravesical Urinary Bladder Neoplasms Oncology 030220 oncology & carcinogenesis BCG Vaccine Female business Non muscle invasive |
| Zdroj: | Urologic Oncology: Seminars and Original Investigations. 39:642-663 |
| ISSN: | 1078-1439 |
| DOI: | 10.1016/j.urolonc.2021.05.015 |
| Popis: | Aim This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Guerin (BCG)-naive, BCG-recurrent, and BCG-unresponsive patient populations are also described, e.g., those involving immune checkpoint inhibitors, targeted therapies, other chemotherapy regimens, vaccines, and viral- or bacterial-based treatments. Finally, a brief overview of enhanced cystoscopy and drug delivery systems for the diagnosis and treatment of NMIBC is provided. Background A global shortage of access to BCG is affecting the management of BCG-naive and BCG-recurrent/unresponsive NMIBC; hence, there is an urgent need to assist patients and urologists to enhance the treatment of this disease. Methods Searches of ClinicalTrials.gov, PubMed, and Google Scholar were conducted. Published guidance and conference proceedings from major congresses were reviewed. Conclusion Treatment strategies for NMIBC are generally consistent across guidelines. Several novel therapies have demonstrated promising antitumor activity in clinical trials, including in high-risk or BCG-unresponsive disease. The detection, diagnosis, surveillance, and treatment of NMIBC have also been improved through enhanced disease detection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect